Peter Voorhees, MD

Peter Voorhees, MD, is from the Levine Cancer Institute.

Articles by Peter Voorhees, MD

Saad Z. Usmani, MD, MBA, FACPMyeloma | July 8, 2025
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
View More
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 3, 2025
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 8, 2025
Experts debate immune escape, inflammation, and early intervention in relapsed/refractory multiple myeloma.
Melissa BadamoMyeloma | June 13, 2025
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
Melissa BadamoMyeloma | June 10, 2025
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
Thomas Martin, MDVideo Insights | May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | May 5, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Thomas Martin, MDVideo Insights | May 5, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
Thomas Martin, MDVideo Insights | May 4, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
Thomas Martin, MDVideo Insights | May 4, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Thomas Martin, MDVideo Insights | May 5, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
Thomas Martin, MDVideo Insights | May 5, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.